Feng Jia, Jiang Longyang, Tang Hui, Si Yuankai, Luo Li, Liu Jing, Hu Dengmin, Huang Yilan
Department of Pharmacy, Southwest Medical University, Luzhou, China.
Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Transl Cancer Res. 2024 Nov 30;13(11):5983-5994. doi: 10.21037/tcr-24-669. Epub 2024 Nov 25.
Phosphorylation-dephosphorylation is one of the most common and critical cellular activities. It is essential for cell cycle control and leads to large changes in protein conformation, which can alter protein function and coordinate multiple functions such as cell metabolism, gene transcription and translation, signaling, growth, differentiation, and apoptosis. Alterations in the phosphorylated proteome have been shown in many cancers. Many phosphatases that catalyze dephosphorylation have been described as oncogenes and tumor suppressors. Papillary renal cell carcinoma (PRCC) is the second most common subtype of kidney cancer, in which most patients diagnosed with PRCC are already in advanced stages with a poor prognosis. It is necessary to identify reliable predictors associated with early diagnosis and prognosis of PRCC. The study used PRCC patients data from The Cancer Genome Atlas (TCGA) database to evaluate dephosphorylation-related genes and build a panel of prognostic gene signatures which predicts accurately the outcome of PRCC patients.
The mutation data, and the fragments per kilobase of exon model per million mapped fragments (FPKM) data together with the corresponding clinical information were downloaded from TCGA database for 288 PRCC patients. Lasso regression algorithm (LASSO) and multivariate Cox regression analysis were performed to produce a panel of risk-related genetic signatures.
We analyzed 417 dephosphorylation-associated genes and, finally, identified 9 genes () and constructed a panel of signatures associated with prognosis. The area under the receiver operating characteristic curve (AUC) value was 0.833 for the prognostic risk score signature. It was confirmed that the risk score was an independent predictor of prognosis [hazard ratio (HR) =1.013, 95% confidence interval (CI): 1.002-1.024, P=0.02].
We identified 9 genes associated with dephosphorylation differentially expressed in PRCC tumor tissues and established the first prognostic model based on dephosphorylation-associated genes in PRCC patients. It was shown to be a valid and reliable prognostic indicator that could predict the prognosis of PRCC patients accurately. This study has a lot of potential value for future studies.
磷酸化-去磷酸化是最常见且关键的细胞活动之一。它对细胞周期调控至关重要,并导致蛋白质构象发生重大变化,进而改变蛋白质功能并协调多种功能,如细胞代谢、基因转录与翻译、信号传导、生长、分化及凋亡。许多癌症中已显示出磷酸化蛋白质组的改变。许多催化去磷酸化的磷酸酶已被描述为癌基因和肿瘤抑制因子。乳头状肾细胞癌(PRCC)是肾癌的第二常见亚型,大多数被诊断为PRCC的患者已处于晚期,预后较差。有必要确定与PRCC早期诊断和预后相关的可靠预测指标。本研究使用来自癌症基因组图谱(TCGA)数据库的PRCC患者数据来评估去磷酸化相关基因,并构建一组预后基因特征,该特征能准确预测PRCC患者的预后。
从TCGA数据库下载了288例PRCC患者的突变数据、每百万映射片段中外显子模型每千碱基的片段数(FPKM)数据以及相应的临床信息。进行套索回归算法(LASSO)和多变量Cox回归分析以生成一组与风险相关的基因特征。
我们分析了417个去磷酸化相关基因,最终鉴定出9个基因,并构建了一个与预后相关的特征组。预后风险评分特征的受试者工作特征曲线(AUC)下面积值为0.833。证实风险评分是预后的独立预测指标[风险比(HR)=1.013,95%置信区间(CI):1.002 - 1.024,P = 0.02]。
我们鉴定出9个在PRCC肿瘤组织中差异表达的与去磷酸化相关的基因,并建立了首个基于PRCC患者去磷酸化相关基因的预后模型。它被证明是一个有效且可靠的预后指标,能够准确预测PRCC患者的预后。本研究对未来研究具有很大的潜在价值。